骨髓状细胞在晚期细胞癌中调解干扰素驱动的免疫治疗耐药性
Kevin Bi1, Soki Kashima2, Sabrina Y Camp1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Immunity
|November 1, 2025
概括
瘤微环境中的干扰素信号导致对癌症免疫疗法的耐药性. 骨髓状细胞,而不是瘤细胞,调解这种抵抗,为改善脏细胞癌中免疫检查点阻塞疗效提供了新的标.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫检查点封锁 (ICB) 是癌症治疗的基石.
- 持续的I型和II型干扰素 (IFN) 信号可能导致对ICB的抵抗.
- 了解瘤微环境 (TME) 中IFN驱动的抗性的细胞机制对于改善治疗结果至关重要.
研究的目的:
- 描述IFN在细胞癌 (RCC) 的TME中的影响.
- 研究IFN诱导的细胞表型如何影响ICB疗效.
- 在RCC中识别IFN驱动的免疫疗法耐药性的细胞介质.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于分析TME.
- 使用混合效应模型推断IFN诱导IFN刺激基因 (ISG) 在不同细胞类型中的IFN诱导性.
- 分析了临床试验队列,以将IFN信号签名与ICB响应相关联.
- 在体外实验中评估了IFN-γ受条件的巨细胞对T细胞杀死RCC细胞的功能影响.
主要成果:
- 编码抑制带和免疫检查点的基因在TME内的巨细胞中表达高,IFN可诱导.
- 这种IFN诱导性在RCC瘤细胞中不那么明显.
- 骨髓IFN-γ信号的签名,但不是瘤IFN-γ信号,预测了临床队列中对ICB加抗VEGF治疗的初级耐药性.
- 在实验室中,IFN-γ刺激的巨细胞抑制了RCC瘤细胞被T细胞杀死.
结论:
- 骨髓状细胞,而不是瘤细胞,是瘤外部的关键调解者,IFN驱动的抗免疫疗法在RCC.
- 在TME中对细胞因子信号效应的推理建模为生物标志物发现提供了一个框架.
- 向骨髓细胞介导的IFN信号通路可以克服细胞癌中对ICB的抗性.
关键词:
国际货币基金网 (IFN) 是一个国际货币基金组织.癌症免疫学 癌症免疫学免疫疗法 免疫疗法免疫疗法耐药性 免疫疗法耐药性干扰子信号传输信号骨髓状细胞是骨髓状细胞的组成部分.细胞癌瘤是细胞癌.瘤免疫学 瘤免疫学与瘤相关的巨细胞.更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.7K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.1K
相关概念视频
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
